Boston Scientific Q4 sales rise 15.9% to $5.286 billion; GAAP EPS $0.45
Boston Scientific reported fourth-quarter 2025 net sales of $5.286 billion, up 15.9 percent from a year earlier, and adjusted EPS of $0.80, above its $0.77 to $0.79 guidance range. GAAP EPS was $0.45, below its $0.48 to $0.52 guidance range, after a $194 million litigation-related net charge. The company also estimated 2026 adjusted EPS of $3.43 to $3.49.
Key points
- Q4 net sales of $5.286 billion, up 15.9 percent reported and 12.7 percent organic, versus guidance of 14.5 to 16.5 percent reported.
- GAAP EPS of $0.45 versus $0.38 a year earlier and guidance of $0.48 to $0.52; adjusted EPS of $0.80 versus $0.70 a year earlier.
- Litigation-related net charges of $194 million in the fourth quarter.
- 2026 guidance: reported net sales growth of 10.5 to 11.5 percent and adjusted EPS of $3.43 to $3.49.
The filing
Written by AI on Nov 8, 2026, 1:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.